fulvestrant has been researched along with Bone Loss, Perimenopausal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, C; He, X; Li, H; Li, L; Wu, W; Yu, X; Zeng, Y | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Emons, G; Friess, SC; Frosch, KH; Gründker, C; Hofbauer, LC; Nisslein, T; Raddatz, D; Schoppet, M; Viereck, V | 1 |
| Andersson, N; Carlsten, H; Egecioglu, E; Islander, U; Lindberg, MK; Löf, E; Movérare-Skrtic, S; Ohlsson, C; Sjögren, K; Swanson, C | 1 |
| Gradishar, WJ; Jordan, VC | 1 |
2 review(s) available for fulvestrant and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Clinical potential of new antiestrogens.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene | 1997 |
3 other study(ies) available for fulvestrant and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Applying vibration in early postmenopausal osteoporosis promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells and suppresses postmenopausal osteoporosis progression.
Topics: Animals; Bone Density; Bone Marrow Cells; Cell Differentiation; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Disease Progression; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Gene Expression Regulation; Humans; Mesenchymal Stem Cells; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; PPAR gamma; Rats; Rats, Sprague-Dawley; Signal Transduction; Tibia; Transcription Factors; Vibration | 2019 |
Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.
Topics: 2-Propanol; Adult; Alkaline Phosphatase; Carrier Proteins; Cell Differentiation; Cells, Cultured; Cimicifuga; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Activation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Gene Expression; Glycoproteins; Humans; Male; Membrane Glycoproteins; Menopause; Osteoblasts; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; Plant Extracts; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Progesterone; Receptors, Tumor Necrosis Factor; RNA, Messenger | 2005 |
Investigation of central versus peripheral effects of estradiol in ovariectomized mice.
Topics: Animals; Bone and Bones; Bone Density; Brain; Dose-Response Relationship, Drug; Drug Implants; Estradiol; Estrogen Antagonists; Female; Femur; Fulvestrant; Humans; Mice; Mice, Inbred C57BL; Middle Aged; Models, Animal; Osteoporosis, Postmenopausal; Ovariectomy; Tibia; Tomography, X-Ray Computed | 2005 |